Overview
Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2028-07-05
2028-07-05
Target enrollment:
0
0
Participant gender:
All
All
Summary
The primary purpose of this study is to characterize the pharmacokinetics and pharmacodynamics of treatment with ravulizumab intravenous infusion in pediatric participants with gMG.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Alexion PharmaceuticalsTreatments:
Ravulizumab
Criteria
Inclusion Criteria:- Diagnosis of gMG confirmed by a positive serologic test for anti-AChR antibodies (Abs)
obtained at Screening and/or during Screening Period
- Myasthenia Gravis Foundation of America (MGFA) Clinical Classification of Class II to
Class IV at Screening
- Participants receiving treatment must be on a stable dosing regimen of adequate
duration prior to Screening and during the Screening Period.
- Eculizumab-experienced participants must have been enrolled and treated with
eculizumab in Study ECU-MG-303 for at least 6 months (180 days) and must have been on
a stable dose for ≥ 2 months (60 days) prior to Screening.
- All participants must be vaccinated against meningococcal infection
Exclusion Criteria:
Medical Conditions
- Any untreated thymic malignancy, carcinoma, or thymoma.
- Participants with a history of treated benign thymoma
- History of thymectomy, thymomectomy, or any thymic surgery within the 12 months prior
to Screening
- History of N meningitidis infection
- Known to be human immunodeficiency virus (HIV) positive
- History of unexplained infections
- Known or suspected history of drug or alcohol abuse or dependence within 1 year prior
to the start of the Screening Period